BioWorld

Jan. 24, 2006

View Archived Issues

Syntonix, Biovitrum In Deal On Long-Acting Clotting Product

Syntonix Pharmaceuticals Inc. agreed to out-license overseas rights to FIX:Fc, its preclinical recombinant Factor IX product for hemophilia B, to Biovitrum AB. (BioWorld Today) Read More

Tanox Earns Xolair Milestone; Peanut Allergy Work In Limbo

Read More

Studying Antibiotic Resistance In Soil, Scientists Hit Pay Dirt

Read More

Young Firm Novelix Growing Portfolio Via USC In-Licensing

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More